Surrogate outcome markers in research and clinical practice

Australian Prescriber

Volumn 32, Issue 2, 2009, Pages 47-50

  Twaddell, Scott ^a  

^a JOHN HUNTER HOSPITAL   (Australia)

Author keywords

Clinical trials; Drug regulation

Indexed keywords

ANTIRETROVIRUS AGENT; BISPHOSPHONIC ACID DERIVATIVE; EZETIMIBE; HEMOGLOBIN A1C; PROSTATE SPECIFIC ANTIGEN; SIMVASTATIN; TORCETRAPIB;

ARTERIAL WALL THICKNESS; ARTICLE; BONE DENSITY; CLINICAL PRACTICE; CLINICAL RESEARCH; CLINICAL TRIAL; DISEASE MARKER; FORCED EXPIRATORY VOLUME; HUMAN; INTRAOCULAR PRESSURE; OPPORTUNISTIC INFECTION; OUTCOME ASSESSMENT; PATIENT SAFETY; PROGNOSIS; VALIDITY;

EID: 65249164099     PISSN: 03128008     EISSN: None     Source Type: Journal    
DOI: 10.18773/austprescr.2009.023     Document Type: Article

References (12)

1. Department of Health and Human Services. Food and Drug Administration. New drug, antibiotic, and biological drug product regulations: accelerated approval. Federal Register Vol 57 No 73. 1992. p. 13234-42.
2. Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled? Ann Intern Med 1996;125:605-13.
3. Barnes D. How prescription drugs are developed. Aust Prescr 2006;29:159-61.
4. Vogel R, Crick RP, Newson RB, Shipley M, Blackmore H, Bulpitt CJ. Association between intraocular pressure and loss of visual field in chronic simple glaucoma. Br J Ophthalmol 1990;74:3-6.
5. Traver GA, Cline MG, Burrows B. Predictors of mortality in chronic obstructive pulmonary disease. Am Rev Respir Dis 1979;119:895-902.
6. Dolan S, Varkey B. Prognostic factors in chronic obstructive pulmonary disease. Curr Opin Pulm Med 2005;11:149-52.
7. Berger VW. Does the Prentice criterion validate surrogate endpoints? Stat Med 2004;23:1571-8.
8. Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 1989;8:431-40.
9. Krumholz HM, Lee TH. Redefining quality - implications of recent clinical trials. N Eng J Med 2008;358:2537-9.
10. Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Eng J Med 2008;358:1431-43.
11. Kanis JA, Borgstrom F, De Laet C, Johansson H, Johnell O, Jonsson B, et al. Assessment of fracture risk. Osteoporos Int 2005;16:581-9.
12. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996;312:1254-9.